
The FDA approved adrabetadex for infantile-onset NPC based on a 55% lower risk of death vs external controls, with a boxed warning for hearing loss.
Not until 1980 did experiences in the care of teenagers become a requirement of pediatric residency training, and not until 1997 was a month-long rotation in adolescent medicine made a mandatory part of residency training.






